Exelon patch to be available in Korea

Published: 2007-04-25 06:56:00

Updated: 2007-04-25 06:56:00

Exelon patch, the first transdermal therapy for Alzheimer's disease, will be likely approved by the Korea Food and Drug Administration, possibly within this year, based on the results of the IDEAL (Investigation of Transdermal Exelon in Alzheimer's disease).

The 24-week IDEAL trial of 1,195 patients with Alzheimer's disease showed that the Exelon Patch provided benefits across a range of sym...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.